Healthifica

Sudden Swelling Can Be Life-Threatening To Some
Pittsburgh Channel.com, PA - Nov 30, 2006… Your child may have hereditary angioedema without you knowing it until he or she unexpectedly begins to develop rapid swelling of various body parts. …
Source: www.thepittsburghchannel.com

PHARMING SHAREHOLDERS APPOINT BRUNO GIANNETTI AS MEMBER OF THE …
Market Wire (press release) - Nov 1, 2006… Pharming has two products in late stage development - Rhucin (recombinant human C1 inhibitor) for hereditary angioedema (under review by EMEA) and human …
Source: www.marketwire.com

The Concession Speech You’ll Probably Never Hear
NPR - Nov 7, 2006… “But as we found out that day, angioedema is a swelling that occurs well beneath the skin, which I think has become a kind of theme for this campaign. …
Source: www.npr.org

Dyax signs deal with Australian agency
Boston Business Journal,  USA - Nov 30, 2006… Dyax is furthest along with DX-88, a potential treatment it is developing with Genzyme Corp. (Nasdaq: GENZ) for hereditary angioedema. …
Source: boston.bizjournals.com

Jerini Reports Financial Results for First Nine Months
PrimeZone (press release), CA - Nov 13, 2006… “Our strong financial position will allow us to achieve our goal of bringing Icatibant, for the subcutaneous treatment of hereditary angioedema, to the …
Source: www.primezone.com

Dyax Announces Final Patient Treated in Pivotal Phase III Clinical …
Business Wire (press release), CA - Nov 21, 2006… of its pivotal Phase III clinical trial, known as EDEMA3, for its lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). …
Source: home.businesswire.com

Dyax to Present at the Cowen and Company Global Health Care …
PharmaLive.com (press release), PA - Nov 2, 2006… In its joint venture with Genzyme Corporation, Dyax has successfully completed three Phase II trials of DX-88 for the treatment of hereditary angioedema (HAE). …
Source: www.pharmalive.com

Breast Cancer
WebMD - Nov 2, 2006… Discontinuation of Herceptin treatment should be strongly considered for patients who develop anaphylaxis, angioedema, or acute respiratory distress syndrome. …
Source: www.webmd.com

Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating …
Drug Newswire (press release), CT - Oct 29, 2006… disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis …
Source: www.drugnewswire.com